. It is time to repeat the feat by eliminating two neglected tropical diseases (NTDs) from the country latest by 2020 -visceral leishmaniasis (VL, kala-azar) and lymphatic filariasis (LF, elephantitis). India has committed itself for control/elimination of these diseases. It is a signatory to the World Health Assembly (WHA) resolutions on leishmaniasis 2 , lymphatic filariasis 3 , and also Resolution on Neglected Tropical Diseases 4 . For various reasons India has, in past, missed the date for elimination of both VL and LF.
By signing these resolutions, India became a part of the global community in its fight against NTDs. There is a renewed global push for control/elimination/ eradication of the 17 NTDs championed by the World Health Organization (WHO). In its stewardship role the WHO has enunciated strategies and policies to combat neglected tropical diseases in its Global Plan 2008-2015 5 , followed by a medium term strategic Plan 2008-2013 6 , and finally in 2012 a road map to guide the implementation of the strategies/policies enunciated in the Global Plan 7 . It set bold targets for control/ elimination/ eradication of the 17 NTDs. The diseases identified for elimination and the period in which this should be accomplished have been arrived at by carefully assessing the current level of understanding of the epidemiology of the diseases and tools available in the armamentarium for their elimination. Global elimination of LF, and regional elimination of VL as public health problem from the Indian Sub-continent have been targeted by the WHO for 2020. To assist the member countries of the Region in elimination of VL from the South-East Asia the Regional Office of the WHO has also prepared a Regional Strategic Framework 8 . In epidemiological terms elimination translates into occurrence of less than one case per 10,000 population at Primary Health Centre (block) level.
Inspired by the WHO's bold initiative, a coalition of diverse partners came together under the banner 'Uniting to Combat NTDs' 9 pledging their commitment in a document called the 'London Declaration on NTDs' to provide support towards attaining the WHO road map targets for ten NTDs which include VL and LF 10 . India is a signatory to this declaration also. The 'Uniting to Combat NTDs' has set up a 'Stakeholders Working Group' which among other tasks tracks the progress towards the elimination and compiles a score card.
In addition to being on the watch-list of the Working Group, there are other compelling reasons for India to accelerate progress towards elimination. Since India contributes a significant proportion to global burden of these diseases (for VL it is 50% 11 , for LF 40%
12
), reduction in India would substantially impact global burden. Elimination of LF and VL will significantly reduce illness and death and will contribute to the Sustainable Development Goals. Reduction of days lost due to ill health will improve the healthy life and subsequent drop in the financial burden of ill health will help to pull families out of poverty. Ensuring the availability of various interventions for VL and LF will improve access to Universal Health Care. and elimination efforts. The new target year is 2017 13 . India has launched a campaign 'Swachh Bharat Abhiyan' (Clean India Mission) in 2014 14 . . An estimated 550-600 million people are at risk of lymphatic filariasis in these districts. The people who suffer from VL and LF are mostly poor socio-economic groups of population primarily living in rural areas. The Ministry of Health and Family Welfare has constituted a Core Group within the Ministry for guidance and oversight of progress towards VL elimination. Based on global, regional and local evidence a National Road Map for VL elimination has also been prepared in 2014 12 . These programmes, among others, have been reviewed by the Joint Missions of the WHO and several areas for strengthening have been identified 15 . Earlier the ICMR has assessed the National Filariasis Control Programme several times 16 . A common observation has been that there are operational problems in efficient implementation of the programmes. Very little operational research has been done; if it has been conducted, the impact of that research is not visible.
Proposed twin-track approach
To ensure that elimination of VL and LF is not lost sight of, it is suggested that the Prime Minister's office (PMO) sets up an Independent Monitoring Board (IMB) on the progress being made on elimination of VL and LF. This Board would have eminent persons -national and international as members. The Board would assess the progress and pitfalls towards the attainment of elimination of VL and LF. If during its meetings the Board concludes that any of the process indicators are at-risk or missed, the relevant State and the NVBDCP would be engaged to establish corrective measures. The IMB would report to the PMO and the reports would also go to the NVBDC, the State Government, and the Minister of Health & Family Welfare. Creation of this Board may elevate the visibility of elimination programme several notches up.
The second track would be to encourage and make funds available for research especially operational variety. Policy Cures' recent report on 'Neglected Diseases Research & Development: Emerging Trends' 17 provides options for additional funds. The Report focuses on product areas for these diseases, including drugs, vaccines, diagnostics, and vector control products. The Government of India emerges as one of the top global funders of neglected diseases R&D. Total public sector funding in India for neglected diseases R&D in 2013 was USD 50 million, making it the world's fifth largest government funder behind the US, the UK and the European Commission and France 17 .
According to another report from Policy Cures 18 majority of Government of India funding is directed towards basic and early-stage research. Despite the impressive amounts of funds being spent on R&D, there are very few examples of Indian organizations being originators of new products be it vaccines, drugs, diagnostics or devices. If need be, some of this fund could be diverted towards programme related research. India should develop a coherent strategic direction towards research in diseases for which it has signed up for elimination. A concerted research strategy is needed to assist the elimination efforts. A more robust framework for bridging the gap between evidence to policy and implementation should become operative.
India has challenges and opportunities. Challenge is to demonstrate that elimination of poliomyelitis is not an exception. Challenge is to maintain the focus on the NTDs in an environment where burden of noncommunicable diseases is increasing. Opportunity lies in evolving image of India. India has become the new economic icon of emerging powers. At predicted GDP (gross domestic product) growth at 7.8 per cent 
